Pharmaceutical composition for treating inflammation in the posterior segment of the eye "gelios"

 

(57) Abstract:

The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of inflammatory processes in the eyeball. The proposed pharmaceutical composition comprises a corticosteroid drug, vegetable and/or animal phospholipids, sodium chloride, sodium phosphate one-deputizing, sodium phosphate disubstituted and purified water in the following ratio, wt.%:

Corticosteroid preparation of 0.001-5

Vegetable and/or animal phospholipids of 0.001-2

Sodium chloride 0,8-0,9

Sodium phosphate one-deputizing of 0.001 to 0.2

Sodium phosphate disubstituted of 0.001 to 0.2

Purified water Rest

The use of this pharmaceutical composition allows us to provide effective and prolonged effects on the inflammation of the eyeball.

The invention relates to medicine, namely to ophthalmology, and is a drug for the treatment of inflammatory processes in the eyeball.

Well-known drug, which drug hormones of the adrenal cortex and is used as anti-inflammatory agents, providing inhib is timido narrowed small vessels and reduced exudation of fluid, reduced accumulation in the area of inflammation leukocytes, decreased activity of macrophages and fibroblasts, as well as reduced production of prostanoids, leukotrienes and factor, platelet-activating (Kharkevich D. A. Pharmacology. M.: Medicine, 1999, S. 405).

However, this drug has a number of significant drawbacks. The drug, dissolved in 0.9% sodium chloride solution, quickly washed out from the cavity of the posterior eye segment, and does not have sufficient buffer capacity, resulting in decreased therapeutic effects of the actual drug and the possible occurrence of local swelling of the cells of the retina due to the lack of a balanced solution.

The technical result of the present invention is prolonged anti-inflammatory effect by maintaining a therapeutic concentration of the drug in the eyeball due to the presence in the composition of phospholipids.

The technical result is achieved in that the pharmaceutical composition (FC) for the treatment of inflammatory diseases in the eyeball includes a corticosteroid drug, vegetable and/or animal phospholipids, sodium chloride, sodium phosphate one-deputizing phosphate on the initial preparation of 0.001-5

Vegetable and/or animal phospholipids of 0.001-2

Sodium chloride 0,8-0,9

Sodium phosphate one-deputizing of 0.001 to 0.2

Sodium phosphate disubstituted of 0.001 to 0.2

Purified water Rest

FC may contain:

Corticosteroid preparation of 0.001-5

Vegetable pospolity of 0.001-2

Sodium chloride 0,8-0,9

Sodium phosphate one-deputizing of 0.001 to 0.2

Sodium phosphate disubstituted of 0.001 to 0.2

Purified water Rest

FC may contain:

Corticosteroid preparation of 0.001-5

Animal and vegetable pospolity of 0.001-2

Sodium chloride 0,8-0,9

Sodium phosphate one-deputizing of 0.001 to 0.2

Sodium phosphate disubstituted of 0.001 to 0.2

Purified water Rest

FC may contain:

Corticosteroid preparation of 0.001-5

Animals pospolity of 0.001-2

Sodium chloride 0,8-0,9

Sodium phosphate one-deputizing of 0.001 to 0.2

Sodium phosphate disubstituted of 0.001 to 0.2

Purified water Rest

Phospholipids have a membrane, prolonging effect and are inhibitors of swelling of the cells of the retina. Their concentration Miz, this concentration can cause unwanted macrophage response.

The concentration of sodium chloride, sodium phosphate and one-deputizing sodium phosphate disubstituted correspond to the solution of normal for the body osmolarity 300-310 mOsm, the concentration of phosphate may not be less than 0.001% due to Hypo osmotic swelling effect and can not be more than 0.2% due to the hyperosmolar effect.

Thus, the proposed pharmaceutical composition for the treatment of inflammatory processes in the eyeball “Gelios” is a drug with an effective long-lasting anti-inflammatory effect.

The pharmaceutical composition Delios receive the following way: the starting substances are mixed under aseptic conditions, filtered through a 0.22 μm filter, packaged and sterilized by autoclaving.

Declared farmacevticheskaja composition “Gelios” is used in acute or chronic inflammatory processes of the posterior eye segment and introduced into the anterior chamber through a paracentesis, and in the vitreous cavity by injection through the pars plana after previously Subtotal vitrectomy.

EXAMPLE 1: Patient Century, 73 years, with a diagnosis of PR is palamau cataract extraction with IOL implantation discovered the threads of the fluid in the vitreous cavity. The patient produced Subtotal vitrectomy and once entered the claimed pharmaceutical composition “Gelios” in the amount of 5 ml in the vitreous cavity by injection through the pars plana of the following composition, wt.%:

Dexamethasone 0.1 To

Phosphatidylcholine 0,08

Sodium chloride 0,9

Sodium phosphate one-deputizing 0,08

Sodium phosphate disubstituted 0,08

Purified water Rest

3 days after administration of the composition of inflammation in the vitreous cavity was absent.

EXAMPLE 2: Patient Z., 29 years old, with a diagnosis of right eye - posttraumatic proveit. At admission the patient had strong pain in the right eye, when biomicroscopy revealed sesenna injection, discoloration of the iris, corneal edema, the phenomenon of Tyndale 3-4 tbsp., with indirect ophthalmoscopy on ONE of the threads of the fluid in the cavity of the ARTICLE. Patients performed a Subtotal vitrectomy and once entered the claimed pharmaceutical composition “Gelios” in front of the camera in the amount of 2 ml by paracentesis, and in the vitreous cavity in an amount of 5 ml by injection through the pars plana of the following composition, wt.%:

Dexamethasone 4,7

Sodium phosphate disubstituted 0,2

Purified water Rest

On the 4th day after the introduction of the proposed pharmaceutical composition by biomicroscopy and indirect ophthalmoscopy showed positive treatment panuveitis: reduction of corneal edema, inflammation in the anterior chamber and the vitreous cavity was absent. On day 7 the absence of corneal edema, the phenomenon of Tyndale.

The fluid in the vitreous cavity remained transparent.

EXAMPLE 3: Patient K., aged 65, with a diagnosis of left eye - chronic uveitis, stage of remission, Mature complicated cataract. After surgery, extracapsular cataract extraction with IOL implantation discovered the threads of the fluid in the vitreous cavity. The patient produced Subtotal vitrectomy and once entered the claimed pharmaceutical composition “Delios in the vitreous cavity in an amount of 5 ml by injection through the pars plana of the following composition, wt.%:

Dexamethasone 0.1 To

Egg phospholipid 0,08

Sodium chloride 0,9

Sodium phosphate one-deputizing 0,08

Sodium phosphate disubstituted 0,08

Purified water was Stalinvestodo.

Pharmaceutical composition for treatment of inflammatory processes in the eyeball containing corticosteroid drug, characterized in that it further comprises a vegetable and/or animal phospholipids, sodium chloride, sodium phosphate one-deputizing, sodium phosphate disubstituted and purified water in the following ratio, wt.%:

Corticosteroid preparation of 0.001-5

Vegetable and/or animal phospholipids of 0.001-2

Sodium chloride 0,8-0,9

Sodium phosphate one-deputizing of 0.001 to 0.2

Sodium phosphate disubstituted of 0.001 to 0.2

Purified water Rest



 

Same patents:

The invention relates to the field of medicine

The invention relates to medicine, in particular to ophthalmology

The invention relates to medicine, in particular to ophthalmology

The invention relates to pharmaceutical industry and relates to pharmaceutical compositions containing 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, to prevent, treatment or inhibition of the development of a simple retinopathy or preproliferative retinopathy; the method of preventing, treating or inhibiting the development of a simple retinopathy or preproliferative retinopathy; and applying the 2-ethoxy-1-[[2'-(1 N-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]the benzimidazole-7-carboxylate
The invention relates to ophthalmology and is intended for the treatment of dry eye syndrome (DES) after suffering ophthalmopathy, as well as for treatment of SHBG other etiology
The invention relates to medicine, namely to ophthalmology, and can be used in the operations
The invention relates to medicine, ophthalmology

The invention relates to medicine, namely to the pharmacy and is used for treatment of keratitis and conjunctivitis

The invention relates to ophthalmology and is intended for operations as retinal detachment and progressive myopia

The invention relates to the field of pharmacy and ointments containing corticosteroids

The invention relates to medicine, namely to the development of new combinations Antiherpes virus effect of actions

The invention relates to new biologically active phosphonate derivative of acyclovir

The invention relates to new biologically active phosphonate derivative of acyclovir

The invention relates to new and nitrate salts of compounds of formulas (I) to(VI), which can be used in medicine for the treatment of bone disorders such as abnormalities in bone and joints

The invention relates to pharmaceuticals, in particular to the means of supporting litaize urinary stones
The invention relates to the field of medicine and relates to means for the prevention and treatment of caries, hyperesthesia, remineralization of hard tissues of teeth
The invention relates to pharmaceutical industry and relates to the creation of a means for inhibiting reproduction enveloped viruses
Up!